Eli Lilly’s UK life sciences investment ‘a pivotal moment’, says analyst
Eli Lilly’s investment is seen as an opportunity to drive economic growth for the UK while improving public health.
Corporate Governance
Nobel laureates ‘strongly urge’ Senate to oppose confirmation of RFK Jr
Vifor Pharma offers £23m to NHS to resolve CMA investigation
FDA shares new draft guidance for accelerated approval
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Trump 2.0 could see a rise in biopharmaceutical M&A deals
Trump 2.0 spells global change in pharmaceutical regulation, funding and investment
Dr Oz nominated to lead CMS despite big pharma ties
